Abstract
Zaleplon is a chemically novel hypnotic that preferentially binds α1-subunit containing subtypes of the αβγ configuration of the γ-aminobutyric acid (GABA)(A) receptor. Zaleplon and the non-subtype-selective hypnotic triazolam occasioned 100% drug-appropriate responding in baboons trained to discriminate lorazepam or pentobarbital from vehicle. Flumazenil shifted the zaleplon generalization gradient at least five-fold to the right. A plasma elimination half-life of 6-8 h for oral 10 mg/kg zaleplon and 0.32 mg/kg triazolam was paralleled by discriminative control for 7 h. Zaleplon maintained self-injection greater than vehicle, as did comparison doses of the similarly selective hypnotic zolpidem and triazolam. Concurrent food-maintained responding increased during self-injection of all three drugs. Preferential binding at this α1-containing GABA(A) subtype did not diminish the benzodiazepine (Bzs)-like behavioral effects of zaleplon. (C) 2000 Elsevier Science Ireland Ltd.
Original language | English (US) |
---|---|
Pages (from-to) | 55-68 |
Number of pages | 14 |
Journal | Drug and alcohol dependence |
Volume | 61 |
Issue number | 1 |
DOIs | |
State | Published - Dec 22 2000 |
Keywords
- Abuse potential
- CL 284,846
- Drug discrimination
- Feeding
- Flumazenil
- Pharmacokinetics
- Self-administr ation
- Triazolam
- Zaleplon
- Zolpidem
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)